Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers | Zendy

Clara T. M. M. de Kanter | Zendy; E. P. H. Colbers | Zendy; Quirine Fillekes | Zendy; Andries J. Hoitsma | Zendy; David M. Burger | Zendy

Open Access

Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers

Author(s) -

Clara T. M. M. de Kanter,

E. P. H. Colbers,

Quirine Fillekes,

Andries J. Hoitsma,

David M. Burger

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp472

Subject(s) - lopinavir , lopinavir/ritonavir , ritonavir , pharmacokinetics , interquartile range , medicine , crossover study , bioavailability , bioequivalence , pharmacology , gastroenterology , human immunodeficiency virus (hiv) , viral load , virology , antiretroviral therapy , pathology , alternative medicine , placebo

To determine the pharmacokinetic profiles of lopinavir and ritonavir in two newly developed generic co-formulations for HIV-infected children (Lopimune paediatric tablets and granules, 100/25 mg of lopinavir/ritonavir, Cipla Pharmaceuticals), and to compare these with the branded product (Kaletra).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research